Tolsura

Tolsura (Itraconazole Capsules) is an azole antifungal medication used to treat various fungal infections in both immunocompromised and non-immunocompromised adult patients. It is indicated for the treatment of blastomycosis, pulmonary and extrapulmonary, histoplasmosis (including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis), and aspergillosis (pulmonary and extrapulmonary) in patients who are intolerant of or refractory to amphotericin B therapy.

Each Tolsura capsule contains 65 mg of itraconazole dispersed in a polymer matrix and encapsulated in a hard gelatin capsule. The inactive ingredients include colloidal silicon dioxide, hypromellose phthalate, magnesium stearate, and sodium starch glycolate.

Tolsura is designed to be up to 90% bioavailable, which means it has improved overall absorption compared to conventional itraconazole. This results in consistent plasma levels, ensuring therapeutic levels are achieved and maintained in both fed and fasted conditions. The FDA recommends taking Tolsura with food to enhance absorption.

Specimens for fungal cultures and other relevant laboratory studies should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of these studies are known, but once the results are available, anti-fungal therapy should be adjusted accordingly.

Tolsura is a reliable option for treating fungal infections, providing effective treatment for a range of conditions in both immunocompromised and non-immunocompromised patients.